July 27, 2016
Results from this study indicated diffusion spectrum basis imaging-quantified axonal loss could serve as an imaging biomarker for the prediction of functional recovery in patients with cervical spondylotic myelopathy who undergo decompression.
Researchers prospectively enrolled patients with cervical spondylotic myelopathy (CSM). Of these, seven patients had mild CSM; five patients had moderate CSM; and two patients had severe CSM. Investigators combined the severe and moderate CSM groups, due to few patients in the severe group, and compared them to seven age-matched controls. Diffusion spectrum basis imaging (DBSI) was used to determine the quantifiable measurements of axon and myelin injuries, cellular inflammation and axonal loss.